Healthleap, a clinical AI platform that works within the EHR to screen hospitalized patients for conditions that might otherwise go undiagnosed, is supporting hospitals in finding at-risk patients sooner. The post Healthleap Raises $38M to Expand AI Screening for Overlooked Conditions in Hospitalized Patients appeared first on MedCity News.

Many hospitals are now trying to use AI to automate processes and free up staff time, running simultaneous pilots to perform as many tasks as possible. This quickly leads to pilot sprawl — a state where organizations can no longer even say which agents are still in active use. The post Why Agentic AI Works in Hospitals When You Strip It Down appeared first on MedCity News.

Happy Health has received FDA clearance for its wearable ring, which continuously measures blood pressure without a cuff or external calibration. The post Happy Health’s Cuffless BP Device Wins FDA Clearance appeared first on MedCity News.

Roche gains global rights to a Rona Therapeutics RNA interference drug designed to target ALK7, a genetically validated target for obesity and other metabolic indications. The growing field of companies pursuing ALK7 includes GSK and Arrowhead Pharmaceuticals. The post Roche Puts Up $100M to Pursue Promising But Competitive New Target in Obesity appeared first on MedCity News.

Medicare policy should be transparent and include appropriate notice and stakeholder input. And when a contractor gets it wrong, there should be a clear and rapid way to stop the harm to patients, their relationship with their doctor and the doctor’s practice. The post Medicare Policy Shouldn’t Be Made in the Shadows appeared first on MedCity News.

Corporate venture funds often chase financial returns while ignoring strategic value. Here’s what it takes to turn healthcare portfolio investments into lasting business impact. The post What Corporate Venture Funds Get Wrong about Strategic Value appeared first on MedCity News.

Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures. The post Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug appeared first on MedCity News.

Outro’s funding included participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah Grey Ventures, SemperVirens, Brock Recovery Group and Pave Health Ventures. The post Outro Raises $7M To Support Safe Deprescribing appeared first on MedCity News.

Investing in pediatric care is not simply a moral imperative. It is one of the most practical long-term investments the healthcare system can make. The post Pediatric Innovation Isn’t a Small-Market Problem, It’s an Incentive Problem appeared first on MedCity News.

Asking the right questions about community support, caregiving responsibilities, emotional well-being, and the availability of trusted social networks can establish important context for a person’s outcomes — and spark conversations about social needs that might never otherwise take place. The post Loneliness And Diabetes: Harnessing an Opportunity for Better Outcomes appeared first on MedCity News.

Register for INVEST Digital Health, scheduled for October 29 in Dallas, for an engaging discussion on the impact of consumer-centered care from diagnostics to employer benefits and more. The post Join Us at INVEST Digital Health for a Conversation on Consumer-Centered Care across the Healthcare Ecosystem appeared first on MedCity News.

The FDA recently published draft guidance on pre-market testing for robotically-assisted surgical devices, raising timely discussion around whether hospital infrastructures are capable of supporting increasingly complex systems.  The post Are Hospital Operating Rooms Ready For FDA’s Expectations for Surgical Robots? appeared first on MedCity News.

Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammation. Meanwhile, Retension Pharmaceuticals will use its IPO cash for mid-stage testing of a next-generation hypertension drug. The post TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance appeared first on MedCity News.

The pace of change in digital innovation has exposed the ever-widening gap between digital health and Pharma commercial teams. As a result, Pharma is missing out on its ability to significantly improve its commercial model, by focusing on efficiencies vs. truly reinventing. The post What Life Sciences Commercial Teams Can Learn from Digital Health appeared first on MedCity News.

Diagnostics and drug development startup Arboretum LifeSciences launched with $30 million in financing. Its executives say analyses of data from its genetic tests both form the basis of partnerships with big pharma and lead to the formation of new biotech companies — all focused on common diseases. The post Startup Arboretum Sprouts, Bringing a Precision Medicine Approach to Common Diseases appeared first on MedCity News.